Combined receptor antagonist stimulation of the hypothalamic-pituitary- adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1347-1352

  Mattsson, Cecilia ^a   Reynolds, Rebecca M ^b   Simonyte, Kotryna ^a   Olsson, Tommy ^a   Walker, Brian R ^b  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MIFEPRISTONE; PLACEBO; SPIRONOLACTONE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 65249109370     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2054     Document Type: Article

References (34)

1. de Kloet ER 1991 Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 12:95-164
2. Seckl JR, Olsson T 1995 Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect? J Endocrinol 145:201-211
3. Walker BR 2007 Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545-559
4. Best R, Nelson SM, Walker BR 1997 Dexamethasone and 11-dehydrodexa-methasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivo. J Endocrinol 153:41-48
5. Sandeep TC, MacLullich AMJ, Noble J, Deary IJ, Walker BR, Seckl JR 2004 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101:6734 - 6739
6. Bertagna N, Bertagna C, Luton J-P, Husson J-M, Girard F 1984 The new steroid analogue RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59:25-28
7. GaillardRC, RiondelA, MullerAF, HerrmannW, BaulieuEE1984 RU486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary adrenal system at a specific time of day. Proc Natl Acad Sci USA 81:3879-3882
8. Kling MA, Whitfield Jr HJ, Brandt HA, Demitrack MA, Kalogeras K, Geracioti TD, Perini GI, Calabrese JR, Chrousos GP, Gold PW 1989 Effects of glucocorticoid antagonism with RU 486 onpituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. Psychopharmacol Bull 25:466-472
9. Kling MA, Demitrack MA, Whitfield Jr HJ, Kalogeras KT, Listwak SJ, DeBellis MD, Chrousos GP, Gold PW, Brandt HA 1993 Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology 57:1082-1091
10. Arvat E, Maccagno B, Giordano R, Pellegrino M, Broglio F, Gianotti L, Maccario M, Camanni F, Ghigo E 2001 Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. J Clin Endocrinol Metab 86:3176-3181
11. Deuschle M, Weber B, Colla M, Muller M, Kniest A, Heuser I 1998 Miner-alocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. Neuroendocrinology 68:355-360
12. Dodt C, Kern W, Fehm HL, Born J 1993 Antimineralocorticoid can renoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology 58:570-574
13. Grottoli S, Giordano R, Maccagno B, Pellegrino M, Ghigo E, Arvat E 2002 The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. J Clin Endocrinol Metab 87:4616-4620
14. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F 2000 Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 25:513-518
15. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H 1998 The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. J Clin Endocrinol Metab 83:3339-3345
16. Bradbury MJ, Akana SF, Dallman MF 1994 Roles of type I and II corti-costeroid receptors in regulation of basal activity in the hypothalamo-pituitary-adrenal axis during the diurnal trough and the peak: evidence for a nonadditive effect of combined receptor occupation. Endocrinology 134:1286-1296
17. Spencer RL, Kim PJ, Kalman BA, Cole MA 1998 Evidence for mineralo- corticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 139:2718-2726
18. Marin P, Darin M, Amemiya T, Andersson B, Jern S, Bjorntorp P 1992 Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 41:882-886
19. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate A, Barabara L 1993 The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 77:341-346
20. Strain GW, Zumoff B, Kream J, Strain JJ, Levin J, Fukushima D 1982 Sex difference in the influence of obesity on the 24 hr mean plasma concentration of cortisol. Metabolism 31:209-212
21. Rosmond R, Dallman MF, Bjorntorp P 1998 Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities. J Clin Endocrinol Metab 83:1853-1859
22. Ljung T, Andersson B, Bengtsson B, Bjorntorp P, Marin P 1996 Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 4:277-282
23. Pasquali R, Ambrosi B, Armanini D, Cavagnini F, Uberti ED, Del RG, de PG, Maccario M, Mantero F, MarugoM, RotellaCM, VettorR2002 Cortisoland ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-responsestudy. J Clin Endocrinol Metab 87:166-175
24. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DEW, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421
25. Jessop DS, Dallman MF, Fleming D, Lightman SL 2001 Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 86:4109-4114
26. Mattsson C, Lai M, Noble J, Yau JL, Seckl JR, Walker BR 2003 Obese Zucker rats have reduced mineralocorticoid receptor and 11 β- hydroxysteroid dehydrogenase type 1 expression in hippocampus -implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity. Endocrinology 144:2997-3003
27. Homer NZ, Reynolds RM, Mattsson C, Bailey MA, Walker BR, Andrew R 2009 Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry. J Chromatogr B 877:497-501
28. Gaillard RC, Poffet D, Riondel AM, Saurat J-H 1985 RU486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 61:1009-1011
29. Ou XM, Storring JM, Kushwaha N, Albert PR 2001 Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. J Biol Chem 276:14299-14307
30. Trapp T, Rupprecht R, Castren M, Reul JM, Holsboer F 1994 Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron 13:1457-1462
31. Andrew R, Phillips DIW, Walker BR 1998 Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806-1809
32. Lottenberg SA, Giannella-Neto D, Derendorf H, Rocha M, Bosco A, Carvalho SV, Moretti AE, Lerario AC, Wajchenberg BL 1998 Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 36:501-505
33. Brogden RN, Goa KL, Faulds D 1993 Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45:384-409
34. Overdiek HW, Merkus FW 1987 The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 5:273-302